BLUE - Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues Providing They Meet Approval

• Bluebird Bio is nearing approval of three potentially curative treatments for severe genetic diseases, although approval has been continually delayed.
• They recently left Europe over pricing disagreements, meaning they must convince US payors of the value of their expensive treatments, but which could bring in strong revenues.
• A relatively stable financial position for a biotech start-up means they can comfortably weather any storms in the near term, but approval failure would spell trouble.

For further details see: